Patent ID: 7838496

Claim:
A compound of the general formula is selected from the group consisting of D Pro- L Pro and L Pro- D Pro; Z and Z 1 are chains of n and, respectively, n′ α-amino acid residues whereby either n is 4 and n′ is 6 or n is 5 and n′ is 7, the positions of said amino acid residues in said chain Z being counted from the N-terminal amino acid and the positions of said amino acid residues in chain Z 1 being counted from the C-terminal amino acid, whereby these amino acid residues are if n is 4 and n′ is 6 the amino acid residues in positions 1 to 4 of the chain Z and in positions 1′ to 6′ in chain Z 1 are: P1: Tyr or Arg; P2: L-citrulline (Cit) or Arg; P3: Cys; P4: Arg-NH 2 ; P1′: Lys or Arg; P2′: Tyr; P3′: Cys; P4′: L-2-naphthylalanine (2-Nal); P5′: Arg; and P6′: Arg; Cys at P3 and P3′ can form a disulfide bridge; and if n is 5 and n′ is 7, the amino acid residues in positions 1 to 5 in chain Z and in positions 1′ to 7′ in chain Z 1 are: P1: Tyr; P2: Arg; P3: Cit; P4: Cys; P5: Arg or Arg-NH 2 P1′: Lys; P2′: Cit; P3′: Tyr; P4′: Cys; P5′: 2-Nal, Trp, L-para-aminophenylalanine (F(pNH 2 )) or L-6-C1-Tryptophan (W(6-C1)); P6′: Arg; P7′: D Arg, Arg, Ac-Arg, iPr-Arg, N-(2-aminoethyl)glycine ((EA)G), N-(3-aminopropyl)glycine ((PrA)G), N-(4-amino-n-butyl)glycine ((BA)G), N-(2-guanidinoethyl)glycine ((EGU)G), N-(3-guanidino-n-propyl)glycine ((PrGU)G), or N-(4-guanidino-n-butyl)glycine ((BGU)G); Cys at P4 and P4′ can form a disulfide bridge or an enantiomer thereof or pharmaceutically acceptable salts thereof.